TY - JOUR AU - Chen, Xiangyu AU - Xiao, Heng AU - Ning, Shuangcheng AU - Liu, Bang AU - Zhou, Huashan AU - Fu, Ting TI - ERCC3 Gene Associated with Breast Cancer: A Genetic and Bioinformatic Study JF - BREAST JOURNAL J2 - BREAST J VL - 2024 PY - 2024 PG - 12 SN - 1075-122X DO - 10.1155/2024/7278636 UR - https://m2.mtmt.hu/api/publication/35331436 ID - 35331436 LA - English DB - MTMT ER - TY - JOUR AU - Soltani, Irdmusa N. AU - Bashi, Zadeh Fakhar H. AU - Heshmati, M. AU - Akbari, M.E. AU - Rahimi, S. TI - Comparison of BRCA1 Gene Expression and CA15-3 Tumor Marker Level in Different Stages of Breast Cancer JF - BREAST JOURNAL J2 - BREAST J VL - 2024 PY - 2024 SN - 1075-122X DO - 10.1155/2024/3461694 UR - https://m2.mtmt.hu/api/publication/35310660 ID - 35310660 N1 - Department of Cell and Molecular Sciences, Faculty of Advanced Sciences and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran Department of Laboratory Science, Chalus Branch, Islamic Azad University, Chalus, Iran Cancer Research Center, Shahid Beheshti, University of Medical Sciences, Tehran, Iran Export Date: 17 September 2024 CODEN: BRJOF Correspondence Address: Bashi Zadeh Fakhar, H.; Department of Laboratory Science, Iran; email: haniyehfakhar@yahoo.com LA - English DB - MTMT ER - TY - JOUR AU - Poikonen-Saksela, Paula AU - Karademas, Evangelos AU - Vehmanen, Leena AU - Utriainen, Meri AU - Kondylakis, Haridimos AU - Kourou, Konstadina AU - Manikis, Georgios C. AU - Kolokotroni, Eleni AU - Argyropaidas, Panagiotis AU - Sousa, Berta AU - Horenczyk, Ruth Pat AU - Mazzocco, Ketti AU - Mattson, Johanna TI - Digital Self-Management Intervention Paths for Early Breast Cancer Patients: Results of a Pilot Study JF - BREAST JOURNAL J2 - BREAST J VL - 2024 PY - 2024 PG - 8 SN - 1075-122X DO - 10.1155/2024/8036696 UR - https://m2.mtmt.hu/api/publication/35309508 ID - 35309508 N1 - Funding Agency and Grant Number: European Union [777167] Funding text: This project received funding from the European Union's Horizon 2020 Research And Innovation Programme under grant agreement no. 777167. We thank Trial Nurse Satu Karjalainen, Physiotherapists Katja Ristimaeki and Minna-Leena Syrjaelae, Psychologists Kati Kajastus and Jan-Henry Stenberg, and Nutrition Therapists Saila Tevaniemi and Pia Nikander for their assistance. AB - Background. Despite excellent prognosis of early breast cancer, the patients face problems related to decreased quality of life and mental health. There is a need for easily available interventions targeting modifiable factors related to these problems. The aim of this study was to test the use of a new digital supportive intervention platform for early breast cancer patients. Material and Methods. Ninety-seven early breast cancer patients answered questions on wellbeing, exercise, and sociodemographic factors before systemic adjuvant treatment at the Helsinki University Hospital. Based on these answers and predictive algorithms for anxiety and depression, they were guided onto one or several digital intervention paths. Patients under 56 years of age were guided onto a nutrition path, those who exercised less than the current guideline recommendations onto an exercise path, and those at risk of mental health deterioration onto an empowerment path. Information on compliance was collected at 3 months on the amount of exercise and quality of life using EORTC-C30 scale, anxiety and depression using HADS scale at baseline and 12 months, and log-in information at 3 and 12 months. Results. Thirty-two patients followed the empowerment path, 43 the nutrition path, and 75 the exercise path. On a scale of 1-5, most of the participants (mean = 3.4; SD 0.815) found the interventions helpful and would have recommended testing and supportive interventions to their peers (mean = 3.70; SD 0.961). During the 10-week intervention period, the mean number of log-ins to the empowerment path was 3.69 (SD = 4.24); the nutrition path, 4.32 (SD = 2.891); and the exercise path, 8.33 (SD = 6.293). The higher number of log-ins to the empowerment (rho = 0.531, P=0.008, and n = 24) and exercise paths (rho = 0.330, P=0.01, and n = 59) was related to better global quality of life at one year. The number of log-ins correlated to the weekly amount of exercise in the exercise path (cc 0.740, P value <0.001, and n = 20). Conclusion. Patients' attitudes towards the interventions were positive, but they used them far less than was recommended. A randomized trial would be needed to test the effect of interventions on patients' QoL and mental health. LA - English DB - MTMT ER - TY - JOUR AU - Madsen, Anna Martha Hammershoi AU - Eefsen, Rikke Helene Lovendahl AU - Nielsen, Dorte AU - Kumler, Iben TI - Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review JF - BREAST JOURNAL J2 - BREAST J VL - 2024 PY - 2024 PG - 15 SN - 1075-122X DO - 10.1155/2024/9083055 UR - https://m2.mtmt.hu/api/publication/35289331 ID - 35289331 LA - English DB - MTMT ER - TY - JOUR AU - Liu, H. AU - Wang, J. AU - Li, Y. AU - Luo, F. AU - Xing, L. TI - Upregulated SAE1 Drives Tumorigenesis and Is Associated with Poor Clinical Outcomes in Breast Cancer JF - BREAST JOURNAL J2 - BREAST J VL - 2024 PY - 2024 SN - 1075-122X DO - 10.1155/2024/2981722 UR - https://m2.mtmt.hu/api/publication/35144931 ID - 35144931 N1 - Department of Breast and Thyroid Surgery, The First Affiliated Hospital, Chongqing Medical University, No. 1 Youyi Rd, Chongqing, 400016, China Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital, Chongqing Medical University, No. 1 Youyi Rd, Chongqing, 400016, China Department of Head Neck and Breast Surgery, The First Affiliated Hospital, USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui, Hefei, 230031, China Department of Head Neck and Breast Surgery, Anhui Provincial Cancer Hospital, Anhui, Hefei, 230031, China Export Date: 24 July 2024 CODEN: BRJOF Correspondence Address: Luo, F.; Department of Breast and Thyroid Surgery, No. 1 Youyi Rd, China; email: luofeng201413@163.com Correspondence Address: Xing, L.; Department of Breast and Thyroid Surgery, No. 1 Youyi Rd, China; email: tiger861220@126.com Chemicals/CAS: cyclin dependent kinase 2, 141349-86-2 LA - English DB - MTMT ER - TY - JOUR AU - Dragvoll, Ida AU - Bofin, Anna M. AU - Soiland, Havard AU - Engstrom, Monica Jernberg TI - How to Optimize Deimplementation of Sentinel Lymph Node Biopsy? JF - BREAST JOURNAL J2 - BREAST J VL - 2024 PY - 2024 PG - 9 SN - 1075-122X DO - 10.1155/2024/7623194 UR - https://m2.mtmt.hu/api/publication/34953737 ID - 34953737 LA - English DB - MTMT ER - TY - JOUR AU - Carlson, Kjirsten A. AU - Checka, Cristina AU - Hunt, Kelly K. AU - Jung, Jennifer AU - Bridges, Christian AU - Singh, Puneet AU - Refnetti, Ana AU - Moseley, Tanya AU - Perez, Frances AU - Mayo, Cody AU - Tamirisa, Nina TI - Evaluation of a Surgical Navigation System for Localization and Excision of Nonpalpable Lesions in Breast and Axillary Surgery JF - BREAST JOURNAL J2 - BREAST J VL - 2023 PY - 2023 PG - 7 SN - 1075-122X DO - 10.1155/2023/9993852 UR - https://m2.mtmt.hu/api/publication/34848848 ID - 34848848 AB - Introduction. Elucent Medical has introduced a novel EnVisio (TM) Surgical Navigation system which uses SmartClips (TM) that generate a unique electromagnetic signal triangulated in 3 dimensions for real-time navigation. The purpose of this study was to evaluate the efficacy and feasibility of the EnVisio Surgical Navigation system in localizing and excising nonpalpable lesions in breast and axillary surgery. Methods. This pilot study prospectively examined patients undergoing breast and nodal localization using the EnVisio Surgical Navigation system. SmartClips were placed by designated radiologists using ultrasound (US) or mammographic (MMG) guidance. The technical evaluation focused on successful deployment and subsequent excision of all localized lesions including SmartClips and biopsy clips. Results. Eleven patients underwent localization using 27 SmartClips which included bracketed multifocal disease (n = 4) and clipped lymph node (n = 1). The bracketed cases were each localized with 2 SmartClips. Mammography and ultrasound were used (n = 8 and n = 19, respectively) to place the SmartClips. All 27 devices were successfully deployed within 5 mm of the targeted lesion or biopsy clip. All SmartClip devices were identified and retrieved intraoperatively. No patients required a second operation for margin excision. Conclusion. In a limited sample, the EnVisio Surgical Navigation system was a reliable technology for the localization of breast and axillary lesions planned for surgical excision. Further comparative studies are required to evaluate its efficacy in relation to the other existing localization modalities. LA - English DB - MTMT ER - TY - JOUR AU - Song, Ji-Eun AU - Jang, Ji Young AU - Kang, Kyung Nam AU - Jung, Ji Soo AU - Kim, Chul Woo AU - Kim, Ah Sol TI - Multi-MicroRNA Analysis Can Improve the Diagnostic Performance of Mammography in Determining Breast Cancer Risk JF - BREAST JOURNAL J2 - BREAST J VL - 2023 PY - 2023 PG - 13 SN - 1075-122X DO - 10.1155/2023/9117047 UR - https://m2.mtmt.hu/api/publication/34612989 ID - 34612989 AB - The objective of this study was to determine whether multi-microRNA analysis using a combination of four microRNA biomarkers (miR-1246, 202, 21, and 219B) could improve the diagnostic performance of mammography in determining breast cancer risk by age group (under 50 vs. over 50) and distinguish breast cancer from benign breast diseases and other cancers (thyroid, colon, stomach, lung, liver, and cervix cancers). To verify breast cancer classification performance of the four miRNA biomarkers and whether the model providing breast cancer risk score could distinguish between benign breast disease and other cancers, the model was verified using nonlinear support vector machine (SVM) and generalized linear model (GLM) and age and four miRNA qRT-PCR analysis values (dCt) were input to these models. Breast cancer risk scores for each Breast Imaging-Reporting and Data System (BI-RADS) category in multi-microRNA analysis were analyzed to examine the correlation between breast cancer risk scores and mammography categories. We generated two models using two classification algorithms, SVM and GLM, with a combination of four miRNA biomarkers showing high performance and sensitivities of 84.5% and 82.1%, a specificity of 85%, and areas under the curve (AUCs) of 0.967 and 0.965, respectively, which showed consistent performance across all stages of breast cancer and patient ages. The results of this study showed that this multi-microRNA analysis using the four miRNA biomarkers was effective in classifying breast cancer in patients under the age of 50, which is challenging to accurately diagnose. In addition, breast cancer and benign breast diseases can be classified, showing the possibility of helping with diagnosis by mammography. Verification of the performance of the four miRNA biomarkers confirmed that multi-microRNA analysis could be used as a new breast cancer screening aid to improve the accuracy of mammography. However, many factors must be considered for clinical use. Further validation with an appropriate screening population in large clinical trials is required. This trial is registered with (KNUCH 2022-04-036). LA - English DB - MTMT ER - TY - JOUR AU - Elnaghi, Khaled Abd Elaziz Ahmed AU - Alghanmi, Hosam Ali AU - Elsamany, Shereef Ahmed AU - Almarzoki, Fathia AU - Elsafty, Mohamed AU - Jaffal, Mohammad TI - Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome JF - BREAST JOURNAL J2 - BREAST J VL - 2023 PY - 2023 PG - 10 SN - 1075-122X DO - 10.1155/2023/8994954 UR - https://m2.mtmt.hu/api/publication/34300441 ID - 34300441 AB - Background. CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. Patients and Methods. In this retrospective study, we recruited patients with metastatic HR-positive and HER2-negative breast cancer. Neutropenia with 1st cycle, palbociclib dose reduction in addition to different clinicopathological and survival data were checked in patients' medical records. Survival outcomes were compared according to the abovementioned factors. Results. We recruited 150 patients who received first-line palbociclib with hormonal therapy. 86% of patients developed 1st cycle neutropenia which was more common in patients with high Ki67. Dose reduction was recorded in 46.7% of patients and it was more common in patients with higher Allred scores (scores 7-8). The median progression-free survival (PFS) of the study group was 22 months. No significant difference was observed in PFS according to the 1st cycle of neutropenia or grade of neutropenia. Similarly, no difference in PFS according to palbociclib dose reduction and HER2 low status was observed. Only the Allred score and having a single site of metastasis had an independent significant relation with PFS. The median overall survival (OS) of the study group was 39 months. No significant difference was observed in OS according to the 1st cycle neutropenia, grade of neutropenia, palbociclib dose reduction, and HER2-low status. Only the Allred score and having a single site of metastasis had an independent significant relation with OS. In addition, no difference was observed in PFS and OS according to ECOG PS (2 vs. 0-1) or menopausal status. Conclusion. No significant impact of the 1st cycle neutropenia, dose reduction, having ECOG PS2, menopausal status, or HER2 low status on survival outcome was observed. Survival outcome was significantly better in patients with single metastatic sites and higher ER-Allred scores. LA - English DB - MTMT ER - TY - JOUR AU - Skafida, E. AU - Andrikopoulou, A. AU - Terpos, E. AU - Markellos, C. AU - Moustafa, S. AU - Pectasides, D. AU - Dimopoulos, M.-A. AU - Zagouri, F. AU - Vassilopoulos, D. TI - Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting JF - BREAST JOURNAL J2 - BREAST J VL - 2023 PY - 2023 SN - 1075-122X DO - 10.1155/2023/3614296 UR - https://m2.mtmt.hu/api/publication/34039665 ID - 34039665 N1 - Department of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University, Athens School of Medicine, Hippokration General Hospital, Athens, Greece Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece Export Date: 29 June 2023 CODEN: BRJOF Correspondence Address: Zagouri, F.; Department of Clinical Therapeutics, Greece; email: florazagouri@yahoo.co.uk LA - English DB - MTMT ER -